Recent findings showed a reduction of CYP46A1 and 24OH levels in AD brains (12, 13), and increasing evidence suggests that CYP46A1 activation may prevent pathological processes occurring in AD (14, 15). This evidence concerns the gene CYP46A1 and Alzheimer disease.